Home / Health / A booster may be needed for J&J firing as the delta variable spreads.

A booster may be needed for J&J firing as the delta variable spreads.

NEW YORK — Infectious disease experts are weighing the need for a vaccine booster. Pfizer/BioNTech or Moderna mRNA for Americans who received Johnson & Johnson’s one-time vaccine due to the greater prevalence of the coronavirus delta outbreak.

Some said they had already done so. Although there is no published data that combining the two different vaccines is safe and effective. or sponsored by US health regulators Canada and some European countries have now allowed people to get two shots of the COVID-1

9 vaccine.

The discussion highlights concerns about how preventable J&J shootings are compared to the delta variant first detected in India and is now spreading widely in several countries, said Rochelle Valenski, director of the Centers for Disease Control and Prevention. Disease (CDC) warns that Delta, which is also associated with more severe disease It could quickly become a dominant virus in the United States.

FDA Adds Rare Heart Inflammation Warning to PFizer, MODERNA COVID VACCINES

There is no significant data on how the J&J vaccine protects against the new variants. However, a UK study showed that two doses of the Pfizer/Bioentech or AstraZeneca vaccine were more protective against the variant. one dose is significant

Ticker safety latest change Change %
JNJ Johnson & Johnson 164.21 +0.84 +0.51%
AZN ASTRAZENECA PLC 59.35 +0.93 +1.59%
PFE Fizer, Inc. 38.98 -0.21 -0.54%

Andy Slavitt, a former senior adviser to President Joe Biden’s pandemic, pitched the idea this week through his podcast. At least half a dozen prominent infectious disease experts say U.S. regulators. Problems need to be solved in a short time.

“There is no doubt that people who have been vaccinated with the J&J vaccine are less prone to disease,” said Professor Dr. Michael Lin from Stanford said. “From the principle of taking simple steps to prevent really bad results. This isn’t easy.”

The CDC does not recommend sponsors. and the agency’s advisors said at a public meeting this week. There is no significant evidence that vaccine protection is reduced.

MODERNA Wins $3.3 Billion Defense Department Contract for More COVID-19 Vaccines

Jason Gallagher, an infectious disease specialist at Temple University’s School of Pharmacy, recently received Pfizer (NYSE:PFE) at a vaccine clinic in Philadelphia. for which he was vaccinated He received the J&J vaccine in a clinical trial in November.

Gallagher said he was concerned about UK data showing lower efficacy compared to the Delta variant for people who received one dose of the vaccine.

“While the situation in the United States has improved greatly, the delta that spread … and rapidly occupied the United States. It looks a little more worrisome in terms of severe infections with single-use vaccines,” he said. “So I jumped on it.”

Hospitalization cases and deaths have declined in the United States, with 56% of the adult population being fully vaccinated.

J&J said it was testing whether the immune response from its vaccine could destroy the delta variant in the lab. but no information yet

Employers can prescribe a COVID-19 vaccine Is it mandatory?

Both mRNA vaccines showed an efficacy rate of approximately 95% in large US trials. Meanwhile, the J&J vaccine is 66% effective in preventing moderate to severe COVID-19 worldwide. When more invasive species

Dr Angela Rasmussen, a researcher at the University of Saskatchewan’s Organization for Vaccines and Infectious Diseases, said on Twitter that she received the Pfizer vaccine this week after receiving the J&J vaccine in April.

Rasmussen, who declined to be interviewed, encouraged Americans vaccinated J&J to talk to doctors about a possible second shooting.

“If you live in a community with low vaccination overall. I highly recommend you consider doing so,” she tweeted.

Dr. Peter Hotez, a vaccine specialist at Baylor College of Medicine, in a tweet said adding a second dose of J&J or one of the mRNA vaccines could offer broader protection. “But we need information and advice from the CDC-FDA.”

Click here to read more about the FOX business.

The US National Institute of Allergy and Infectious Diseases (NIAID) is conducting trials to determine the need to promote all currently permitted vaccinations with another dose of Moderna vaccine. Begel, a NIAID scientist, told Reuters that The agency hopes to receive that information by September. To help inform regulators’ decisions regarding sponsors

As long as the number of cases remains low in the United States, J&J recipients should wait for more information, he said.

If delta variable-driven infections and hospitalizations increase dramatically, he said, “then they may have to make decisions without data, but now I think they deserve to wait.”

Source link